Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04920318 · ClinicalTrials.gov registry record · NA

Enhancing Language Function in Primary Progressive Aphasia

A NA study of Primary Progressive Aphasia, sponsored by University of Arizona.

Recruiting
Registry status
NA
Development phase
20
Enrollment target
1
Study location

NCT04920318 is a NA study of Primary Progressive Aphasia that is actively recruiting participants, run by University of Arizona. The registered enrollment target is 20 participants, below the 91-participant average among 15 other Primary Progressive Aphasia trials with a reported enrollment target (78% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04920318, a NA study of Primary Progressive Aphasia, is actively recruiting participants, sponsored by University of Arizona.

RECRUITING
Registry status
NA
Development phase
20 participants
Enrollment target
1
Study location

Study Summary

This study's goal is to use non-invasive brain stimulation (NBS) techniques to treat language impairment associated with Primary Progressive Aphasia (PPA). The purpose of this study is to combine behavioral language intervention with individualized noninvasive brain stimulation techniques, called transcranial direct current stimulation (tDCS) to help the brain reorganize around damage and improve language functions.

Interventions

  • COMBINATION_PRODUCT tDCS + language therapy
  • COMBINATION_PRODUCT sham TDCS + language therapy

Study Locations (1)

Arizona

  • University of Arizona - Tucson

Trial Details

FieldValue
Enrollment Target 20 participants
Start Date 2021-08-30
Est. Completion 2027-06-15
Phase NA

Sponsor

University of Arizona

349 total trials

What the Registry Record Tells You About NCT04920318

The ClinicalTrials.gov registry entry for NCT04920318 describes a study currently listed as recruiting, categorized as NA. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 91-participant average among 15 other Primary Progressive Aphasia trials with a reported enrollment target (78% lower). The listed sponsor is University of Arizona, which has 349 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Primary Progressive Aphasia appearing as the primary indexed condition, and to 2 interventions - of which tDCS + language therapy is the first listed.

NCT04920318 reports 1 study location spanning 1 distinct geographic area - top geographies include Arizona.

Frequently Asked Questions

What is clinical trial NCT04920318 about?

NCT04920318 is a clinical study titled "Enhancing Language Function in Primary Progressive Aphasia". This study's goal is to use non-invasive brain stimulation (NBS) techniques to treat language impairment associated with Primary Progressive Aphasia (PPA). The purpose of this study is to combine behavioral language intervention with individualized noninvasive brain stimulation techniques, called tr...

What is the current status of trial NCT04920318?

This trial is currently recruiting. It is a NA study. The enrollment target is 20 participants. The study started on 2021-08-30. Estimated completion is 2027-06-15.

What conditions does trial NCT04920318 study?

This clinical trial studies the following conditions: Primary Progressive Aphasia.

What interventions are being tested in trial NCT04920318?

The interventions under investigation include: tDCS + language therapy (COMBINATION_PRODUCT), sham TDCS + language therapy (COMBINATION_PRODUCT).

Who is sponsoring clinical trial NCT04920318?

This trial is sponsored by University of Arizona, which has 349 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT04920318 being conducted?

This trial has 1 study location across Arizona. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Primary Progressive Aphasia

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.